Your browser doesn't support javascript.
loading
Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene.
Dicks, Ed; Song, Honglin; Ramus, Susan J; Oudenhove, Elke Van; Tyrer, Jonathan P; Intermaggio, Maria P; Kar, Siddhartha; Harrington, Patricia; Bowtell, David D; Group, Aocs Study; Cicek, Mine S; Cunningham, Julie M; Fridley, Brooke L; Alsop, Jennifer; Jimenez-Linan, Mercedes; Piskorz, Anna; Goranova, Teodora; Kent, Emma; Siddiqui, Nadeem; Paul, James; Crawford, Robin; Poblete, Samantha; Lele, Shashi; Sucheston-Campbell, Lara; Moysich, Kirsten B; Sieh, Weiva; McGuire, Valerie; Lester, Jenny; Odunsi, Kunle; Whittemore, Alice S; Bogdanova, Natalia; Dürst, Matthias; Hillemanns, Peter; Karlan, Beth Y; Gentry-Maharaj, Aleksandra; Menon, Usha; Tischkowitz, Marc; Levine, Douglas; Brenton, James D; Dörk, Thilo; Goode, Ellen L; Gayther, Simon A; Pharoah, D P Paul.
Affiliation
  • Dicks E; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
  • Song H; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
  • Ramus SJ; School of Women's and Children's Health, University of New South Wales, Sydney, Australia.
  • Oudenhove EV; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, Australia.
  • Tyrer JP; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
  • Intermaggio MP; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
  • Kar S; School of Women's and Children's Health, University of New South Wales, Sydney, Australia.
  • Harrington P; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
  • Bowtell DD; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
  • Group AS; Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
  • Cicek MS; Department of Biochemistry and Molecular Biology, University of Melbourne, Melbourne, Victoria, Australia.
  • Cunningham JM; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
  • Fridley BL; Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, UK.
  • Alsop J; Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
  • Jimenez-Linan M; Westmead Millennium Institute, Westmead Hospital, Sydney, Australia.
  • Piskorz A; The QIMR Berghofer Medical Research Institute, Brisbane, Australia.
  • Goranova T; Mayo Clinic, Rochester, Minnesota, USA.
  • Kent E; Mayo Clinic, Rochester, Minnesota, USA.
  • Siddiqui N; Department of Biostatistics, University of Kansas Medical Center, Kansas City, Kansas, USA.
  • Paul J; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
  • Crawford R; Department of Histopathology, Addenbrooke's Hospital, Cambridge, UK.
  • Poblete S; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
  • Lele S; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
  • Sucheston-Campbell L; MRC Clinical Trials Unit, University College London, London, UK.
  • Moysich KB; Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, Scotland.
  • Sieh W; Dept Gynaecol Oncology, Glasgow Royal Infirmary, Glasgow, Scotland.
  • McGuire V; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Lester J; Department of Gynecological Oncology, Roswell Park Cancer Institute, Buffalo, New York, USA.
  • Odunsi K; Department of Gynecological Oncology, Roswell Park Cancer Institute, Buffalo, New York, USA.
  • Whittemore AS; Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York, USA.
  • Bogdanova N; Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York, USA.
  • Dürst M; Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, California, USA.
  • Hillemanns P; Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, California, USA.
  • Karlan BY; Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Gentry-Maharaj A; Department of Gynecological Oncology, Roswell Park Cancer Institute, Buffalo, New York, USA.
  • Menon U; Department of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, California, USA.
  • Tischkowitz M; Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
  • Levine D; Radiation Oncology Research Unit, Hannover Medical School, Hannover, Germany.
  • Brenton JD; Mother and Child Hospital, Minsk, Belarus.
  • Dörk T; Department of Obstetrics and Gynaecology, Friedrich-Schiller University, Jena, Germany.
  • Goode EL; Clinics of Obstetrics and Gynaecology, Hannover Medical School, Hannover, Germany.
  • Gayther SA; Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Pharoah DPP; Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK.
Oncotarget ; 8(31): 50930-50940, 2017 Aug 01.
Article in En | MEDLINE | ID: mdl-28881617

Full text: 1 Database: MEDLINE Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: Oncotarget Year: 2017 Type: Article Affiliation country: United kingdom

Full text: 1 Database: MEDLINE Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: Oncotarget Year: 2017 Type: Article Affiliation country: United kingdom